ARXX Therapeutics ApS — Credit Rating and Financial Key Figures

ARXX Therapeutics ApS (CVR number: 40868151) is a company from HERLEV. The company reported a net sales of 2.8 mDKK in 2023, demonstrating a decline of -51.8 % compared to the previous year. The operating profit percentage was at 8.5 % (EBIT: 0.2 mDKK), while net earnings were 269.8 kDKK. The profitability of the company measured by Return on Assets (ROA) was 24.2 %, which can be considered excellent and Return on Equity (ROE) was 36.9 %, which can be considered excellent. The equity ratio, a key indicator for solidity, stood at 70.9 %, a level that can be considered to be good. This shows that a large part of the company's assets are funded by shareholders' equity, reducing financial risk. ARXX Therapeutics ApS's liquidity measured by quick ratio was 4.2 which is at a very high level. Thus, the company demonstrates exceptional financial stability, possessing a significant surplus of liquid assets over its short-term liabilities.